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Abstract
Background: There have only been a few reports about use of dipeptidyl peptidase 4 (DPP-4) inhibitors in elderly
patients with type 2 diabetes mellitus (T2DM), suggesting that the safety of these agents has not been sufficiently
demonstrated. We performed a comparative review of the efficacy and safety of sitagliptin for Japanese patients
with T2DM managed in the real-world clinical setting.
Methods: An age-stratified analysis was performed of 831 patients who were treated with sitagliptin for 2 years.
Parameters assessed included the hemoglobin A1c (HbA1c), body weight, serum creatinine, and adverse events.
HbA1c and the incidence of hypoglycemia were also evaluated in patients treated with sitagliptin and a sulfonylurea
(SU), who were divided into three age groups (<65 years, 65–74 years, and ≥75 years).
Results: Comparison of glycemic control parameters, laboratory values, and adverse events revealed significant
improvement of HbA1c, casual postprandial plasma glucose, and fasting plasma glucose in each age group with no
change in body weight. Serum creatinine increased significantly in all age groups. Hypoglycemia only occurred in
patients who received combined treatment with an SU and sitagliptin, and there was no age-related difference in
its incidence.
Conclusions: HbA1c was improved by 2 years of sitagliptin therapy in all three age groups, and age did not seem
to influence the incidence of hypoglycemic events. These results confirm the efficacy and safety of sitagliptin in
patients ≥ 75 years old, suggesting that it is also useful for treating elderly patients with T2DM.
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Background
Elderly patients with type 2 diabetes mellitus (T2DM)
are susceptible to osteoporosis [1] and dementia [2], as
well as better-known complications such as diabetic mi-
croangiopathy and macroangiopathy, and the mortality
rate of elderly patients with diabetes is twice that of
non-diabetic elderly persons [3]. To maintain a good
quality of life for patients with T2DM and improve their
prognosis, it is important to achieve appropriate gly-
cemic control with diet and exercise plus pharmacother-
apy as required.
Oral hypoglycemic drugs can cause various adverse
reactions, including hypoglycemia, weight gain, fluid re-
tention, cardiac failure, and gastrointestinal symptoms
[4–6]. In particular, hypoglycemia is associated with
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cardiovascular events and cognitive dysfunction and it
is known that hypoglycemic episodes can lead to falls
and fractures [7]. Elderly patients are more likely to de-
velop hypoglycemia than younger patients when treated
with multiple drugs, as well as immediately after dis-
charge from hospital, if they have renal failure, and if
their diet is poor, and they are also less likely to detect
the onset of hypoglycemia [8, 9]. These differences
make treatment of diabetes more difficult in elderly pa-
tients, so that careful education and drug selection are
required.
Sitagliptin was the first dipeptidyl peptidase 4 (DPP-4)
inhibitor to be released for clinical use. It is an oral
hypoglycemic drug with a glucose-dependent mechan-
ism of action via glucagon-like peptide 1 and glucose-
dependent insulinotropic polypeptide, which makes it
less likely to cause hypoglycemia [10, 11]. In addition,
sitagliptin does not cause weight gain and is expected to
protect the pancreatic beta-cells, suggesting that it is an
appropriate drug for elderly patients [12–16]. However,
there have only been a few reports about use of DPP-4
inhibitors in elderly patients with T2DM, and the safety
of sitagliptin has not been demonstrated sufficiently.
We previously investigated the efficacy and safety of
sitagliptin for Japanese T2DM patients treated in the
real-world setting [17]. In the present study, we per-
formed a post hoc age-stratified analysis of the subjects
who received sitagliptin therapy for 2 years in the previ-
ous study to evaluate its efficacy and safety for elderly
T2DM patients.
Methods
We previously performed a multicenter cohort study of
Japanese T2DM patients to investigate the efficacy and
safety of sitagliptin in the real-world setting [17, 18].
Briefly, 28 hospitals specializing in diabetes and belong-
ing to the Study Group of the Diabetes Committee of
the Kanagawa Physicians Association participated in the
study, which enrolled patients on diet and exercise ther-
apy as well as patients with poor glycemic control
(hemoglobin A1c [HbA1c] ≥ 6.9 % and the primary phys-
ician considered intervention necessary) despite treat-
ment with hypoglycemic agents. After giving consent to
participation, the patients started sitagliptin therapy with
or without other hypoglycemic medications. Sitagliptin
could be up-titrated or down-titrated from the initial
dose (25 or 50 mg), and other T2DM medications with a
different mechanism of action could be added at the dis-
cretion of the primary physician. A total of 1332 patients
were enrolled between 2009 and 2010. This study was
performed at 28 clinics specializing in the treatment of
diabetes by diabetologists who shared information
through periodic study sessions.
Hypoglycemia was diagnosed if HbA1c was ≤ 70 mg/dL
or typical hypoglycemic symptoms were confirmed by
the primary physician, in conformity with the definition
of the American Diabetes Association (ADA) [19]. The
goal of treatment was to achieve an HbA1c <6.9 % irre-
spective of the patient’s age, based on the Japanese guide-
lines around 2009–2010 when this study was started.
While exercising due care to avoid hypoglycemic events,
treatment was provided to achieve an HbA1c <6.9 % from
the perspective of preventing diabetic complications.
In the present post hoc study, we performed age-
stratified analysis by dividing the 831 patients who
were treated for 24 consecutive months into three
groups: <65 years old, 65–74 years old, and ≥75 years
old. The study endpoints included HbA1c, casual post-
prandial plasma glucose [20], body weight, serum cre-
atinine, estimated glomerular filtration rate (eGFR),
and adverse events.
We also assessed HbA1c and the incidence of
hypoglycemic episodes in patients treated with the com-
bination of sitagliptin and a sulfonylurea (SU). Although
there were no definite criteria for SU selection in this
study, the recommendation issued by the Committee on
Proper Use of Incretins [21] was followed by participating
physicians, which meant that the maximum doses of gli-
mepiride, gliclazide, and glibenclamide were 2 mg, 40 mg,
and 1.25 mg, respectively.
Results are presented as the mean ± standard devi-
ation. Analysis of variance (ANOVA) was employed to
assess differences and the level of significance was set at
p < 0.05 (two-tailed). All analyses were performed using
SPSS version 19 for Windows.
This study was approved by the Ethics Review Board
of the Kanagawa Physicians Association.
Results
The characteristics of the 1332 patients registered in the
ASSET-K study and those of the 831 patients with 2-
year data are shown in Table 1. The 831 patients were
divided into three age groups for further analysis (Table 2).
In patients aged <65 years, HbA1c showed a significant de-
crease (p < 0.05) from 8.1 ± 1.2 % at the start of add-on
treatment with sitagliptin to 7.4 ± 1.0 % at 12 months and
7.3 ± 0.9 % at 24 months. There was also a significant de-
crease (p < 0.05) in HbA1c in patients aged 65–74 years
(7.6 ± 0.9 %, 7.0 ± 0.7 %, and 7.0 ± 0.7 %, respectively). Fur-
thermore, HbA1c decreased significantly (p < 0.05) in pa-
tients aged ≥75 years (7.7 ± 0.9 %, 7.1 ± 0.7 %, and 7.1 ±
1.1 %, respectively) (Fig.1). There was no significant
change in body weight in any of the age groups (Fig. 2).
Fasting and casual postprandial glucose levels showed
a significant decrease at 12 and 24 months compared
with the start of add-on sitagliptin therapy in all age
groups (p < 0.05) (Figs. 3 and 4).
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Assessment of renal function showed that serum cre-
atinine was significantly increased at 24 months in all
age groups (Fig. 5).
Adverse events reported in at least 2 patients included
hypoglycemia (n = 58, confirmed by the primary phys-
ician with reference to the ADA definition), constipation
(n = 8), rash (n = 5), diarrhea (n = 2), edema (n = 2), and
nausea (n = 2). Pancreatitis was suspected in a 42-year-
old man due to elevation of amylase, which improved
after discontinuation of sitagliptin.
The 58 patients with hypoglycemia were all receiving
sitagliptin combined with an SU drug. Therefore, we an-
alyzed all of the patients treated with sitagliptin plus an
SU (529 out of 831 patients) (Table 3). There was no dif-
ference in the changes in HbA1c during the 2-year study
period between the whole patient population and those
treated with sitagliptin plus an SU (Table 4). When the
529 patients were analyzed further and divided into
three age groups, the incidence of hypoglycemia was
5.73 events per 100 patients years in patients aged <65 years,
5.79 events per 100 patients years in those aged 65–74
years, and 3.90 events per 100 patients years in those
aged ≥75 years (Fig. 6).
Discussion
The Diabetes Committee of the Kanagawa Physicians
Association conducted the ASSET-K study involving
over 1,000 patients [17, 18, 22–25], and concluded that
factors influencing the reduction in HbA1c by sitagliptin
in patients also taking other oral antidiabetic agents
were a high baseline HbA1c, short duration of diabetes,
and low body mass index at the initiation of sitagliptin
therapy. Because insufficient evidence was available re-
garding the safety of sitagliptin therapy for elderly pa-
tients, age-stratified analysis of safety and efficacy was
performed in the present study.
Although there was the potential for selection bias
when the 1332 patients registered for the study were re-
duced to 831 patients with 2-year data, we performed
analysis of the latter group after confirming that the pa-
tient characteristics of both groups were similar. This
post hoc analysis of ASSET-K data involving 831 pa-
tients with T2DM treated in the real-world clinical set-
ting demonstrated that sitagliptin was both safe and
effective for elderly patients, a group for which there is
particular concern about adverse reactions. HbA1c was
improved by 2 years of sitagliptin therapy in patients
aged <65 years, 65–74 years, and 75 years or older, al-
though the magnitude of the HbA1c reduction varied
due to heterogeneity of the baseline level. There was no
significant change in body weight in any age group and
weight remained steady for 24 months. Among pa-
tients treated with sitagliptin plus an SU, episodes of
Table 1 Characteristics of patients registered in ASSET-K and






Age (years) 62.9 ± 11.6 63.3 ± 10.9
Sex (male/female) 751/581 469/362
Duration of diabetes (years) 12.0 ± 8.1 12.3 ± 8.3
Body mass index 24.6 ± 4.3 24.6 ± 4.2
Concomitant medications (%)
No other OADs 20.0 18.4
1 other OAD 36.0 31.5
2 other OADs 31.0 33.3
≥ 3 other OADs 13.0 16.8
OAD, oral antidiabetic drug
Data are presented as the mean ± standard deviation unless
otherwise indicated
Table 2 Characteristics of the 831 patients stratified into three age groups
Age group P value
<65 years 65–74 years ≥75 years
n (%) 423 (50.9) 282 (33.9) 126 (15.2)
Age (years) 54.8 ± 7.8 69.4 ± 2.8 78.2 ± 3.0 <0.0001*
Sex (male/female) 271/152 141/141 57/69 <0.0001†
Duration of diabetes (years) 9.3 ± 5.9 14.7 ± 8.8 16.8 ± 9.9 <0.0001*
Body mass index 25.5 ± 4.6 23.5 ± 3.5 23.7 ± 3.3 <0.0001*
Concomitant medications (%)
Sulfonylureas 61.9 67.4 61.1 0.2763†
Biguanides 56.7 50.0 34.9 <0.0001†
Thiazolidinediones 27.2 22.3 22.2 0.2764†
Alpha-glucosidase inhibitors 9.2 8.9 11.9 0.5763†
Data are presented as the mean ± standard deviation unless otherwise indicated
*One-way analysis of variance, †Fisher’s exact test
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hypoglycemia showed a similar incidence in all age
groups and did not become more frequent with in-
creasing age. On the other hand, serum creatinine in-
creased significantly and eGFR decreased significantly
after the start of add-on sitagliptin therapy. As re-
ported previously, the diuretic effect of glucagon-like
peptide 1 (which is increased by sitagliptin) leads to
elevation of serum creatinine, as also occurs in patients
treated with diuretics [22, 25]. Serum creatinine in-
creased slightly in the early treatment period, but
subsequently remained steady, suggesting that deteri-
oration of renal function was not progressive during
sitagliptin therapy. There was no marked increase in
serum creatinine in patients aged ≥75 years after
2 years of treatment in the present study, which an im-
portant finding with regard to the safety of sitagliptin
for elderly patients.
A separate age-stratified analysis was also performed
in patients using sitagliptin concomitantly with SUs,
which showed no age-related differences of efficacy or
Fig. 1 Changes in HbA1c over the 2-year observation period. ANOVA, analysis of variance; HbA1c, hemoglobin A1c
Fig. 2 Changes in body weight over the 2-year observation period. ANOVA, analysis of variance
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the incidence of hypoglycemia. After medications that in-
fluence incretins became available, frequent hypoglycemic
episodes were reported in patients taking these agents
concomitantly with SUs, leading the Japan Diabetes Soci-
ety to issue a statement about appropriate use [21]. In the
present study, there was no age-related difference in the
incidence of hypoglycemia. This study was conducted by
diabetes specialists at diabetes clinics and appropriate SU
dosages were tailored for each patient in response to the
Japan Diabetes Society statement, which may have re-
duced the incidence of hypoglycemia in our elderly
patients.
When combined with sitagliptin, gliclazide (which does
not act on Epac2A) is less likely to cause hypoglycemia
than glimepiride or glibenclamide (which act on Epac2A)
[26]. In the present study, few patients received gliclazide
and the incidence of hypoglycemic events was low, which
made it difficult to assess differences among these agents.
Fig. 3 Changes in casual postprandial plasma glucose over the 2-year observation period. ANOVA, analysis of variance; cPPG, casual postprandial
plasma glucose
Fig. 4 Changes in fasting plasma glucose over the 2-year observation period. ANOVA, analysis of variance; FPG, fasting plasma glucose
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In addition, the glibenclamide dosage was relatively low in
patients aged 75 years or older, possibly because the at-
tending physicians considered it desirable to treat elderly
patients with lower doses in order to avoid hypoglycemia.
In the present study, pancreatitis was suspected in a
42-year-old man, but the causal relation with sitagliptin
therapy is unclear. Butler et al. suggested that incretin-
related drugs might induce pancreatitis and pancreatic
carcinoma [27]. However, a pooled analysis of clinical
trials involving sitagliptin did not show any increase of
these conditions. Likewise, no increase of pancreatitis or
pancreatic carcinoma was detected in recent large-scale,
placebo-controlled, double-blind trials of DPP-4 inhibi-
tors, including SAVOR-TIMI 53 and EXAMINE. Further-
more, a retrospective cohort study of Japanese diabetic
patients suggested that treatment with DPP-4 inhibitors
does not increase the risk of acute pancreatitis [28]. The
prospective TECOS study is currently examining the risk
Fig. 5 Changes in serum creatinine over the 2-year observation period. ANOVA, analysis of variance
Table 3 Characteristics of 529 patients receiving sitagliptin plus SU therapy stratified into three age groups
Age group P value
<65 years 65–74 years ≥75 years
n (%) 262 (49.5) 190 (35.9) 77 (14.6)
Age (years) 54.9 ± 7.6 69.5 ± 5.7 77.9 ± 2.9 <0.0001*
Sex (male/female) 143/119 110/80 43/34 0.7853†
Duration of diabetes (years) 10.3 ± 6.0 15.7 ± 9.6 18.6 ± 10.1 <0.0001*
Body mass index 25.8 ± 4.7 23.7 ± 3.8 24.4 ± 4.4 <0.0001*
Type of SU (%)
Glimepiride 70.6 75.3 71.4 0.5391†
Glibenclamide 17.9 14.7 18.2 0.6295†
Gliclazide 11.5 10.0 10.4 0.8803†
Dose of SU (mg)
Glimepiride 1.9 ± 1.3 2.0 ± 7.4 1.6 ± 1.1 0.9354*
Glibenclamide 4.7 ± 2.5 4.4 ± 2.9 3.0 ± 2.3 0.0007*
Gliclazide 37.7 ± 26.4 35.8 ± 32.2 43.3 ± 21.2 0.2708*
SU, sulfonylurea
Data are presented as the mean ± standard deviation unless otherwise indicated
*One-way analysis of variance, †Fisher’s exact test
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of pancreatitis and pancreatic carcinoma in patients
treated with sitagliptin [29, 30], and the results are ex-
pected to provide more insight into this issue.
A recent analysis stratified by renal function was per-
formed in the SAVOR-TIMI 53 Trial, a large-scale clin-
ical study of 16492 patients with T2DM that evaluated
the impact of saxagliptin (another DPP-4 inhibitor) on
cardiovascular disorders. It was found that the efficacy
of saxagliptin did not depend on renal function and the
drug improved microalbuminuria compared with pla-
cebo in patients who had renal impairment [31].
HOMA-2β, an indicator of pancreatic beta-cell function,
decreased in the placebo group, but increased in the sax-
agliptin group after 2 years of treatment [32]. Many eld-
erly patients show impairment of pancreatic or renal
function, but the above-mentioned results suggest that
long-term treatment with DPP-4 inhibitors may help to
preserve residual function.
This study had several limitations. First, there might
have been selection bias since this was a retrospective
observational investigation without control groups. Sec-
ond, we only performed analysis of 831 patients from
among those registered, although clinical characteristics
did not differ between this subgroup and the whole pa-
tient population. Third, we had limited information
about changes of concomitant medications during the
study period, and there were no restrictions regarding
the use of concomitant drugs in daily clinical practice.
Finally, hypoglycemia might have been underdiagnosed,
particularly asymptomatic hypoglycemia that is not un-
common in elderly patients, because detection is largely
dependent on symptoms in daily practice. Thus, our
findings should be interpreted while taking these limita-
tions into consideration.
Conclusions
This post hoc analysis of the ASSET-K study assessed
the efficacy and safety of sitagliptin therapy in elderly
Japanese patients with T2DM. It demonstrated that sita-
gliptin improves HbA1c without causing hypoglycemia
even in patients aged ≥75 years.
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